COMPREHENSIVE PAGES 2019 MARKET ESTIMATE...Steroids 3.7% 1.1% Ophthalmic Labeled Anti-VEGF 89.5% Other 3.5% ENTERPRISE LICENSE 2019 Retinal Pharmaceuticals Market Report $10,950 (Price
Post on 30-Jun-2020
0 Views
Preview:
Transcript
13421 Manchester Road, Ste. 201 | St. Louis, MO 63131 | 314.835.0600 | market-scope.com
A Global Analysis for 2018 to 2024
2019 Retinal Pharmaceuticals Market Report
®
289COMPREHENSIVE
PAGES2019 MARKET
ESTIMATE
$13B
33COMPANY PROFILES
GEOGRAPHIC AND ECONOMIC BREAKOUTS
8
The “2019 Retinal Pharmaceuticals Market Report” features a new disease model based on disease prevalence by ethnicity, a new discussion on issues with syringes used for IVT injections, new analysis on the competitive features of different drug products, and a new section on orally administered drug candidates in development. The report examines more development-stage programs, biosimilars, gene therapies, anti-inflammatories, and sustained drug-delivery devices. Sales forecasts have been updated through 2024.
AUTHOR Peter DownsPUBLISHED September 2019
What’s New
2019 Retinal Pharmaceuticals Market Report
The 2019 Retinal Pharmaceuticals Market Report analyzes the market for the treatment of retinal diseases and discusses important trends and key factors for future market success. It examines the market’s evolution and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Also covered in this report:
Discussions of retinal diseases and their risk factors; Diagnosis and treatment of these diseases; A global view of retinal care and retina specialists; Retinal pharmaceuticals and biologics in the marketplace; Investigational agents in the development pipeline; Profiles of companies developing and marketing retinal pharmaceuticals, plus a listing of additional
companies with preclinical programs.
$13BIN MANUFACTURER REVENUES IN 2019
215%
14%
1.1%
22%
10
3.3%
IVT Compounded Cancer Drugs
5.
Sustained-Release Steroids
3.7%
1.1%
Ophthalmic Labeled Anti-VEGF
89.5%
Other
3.5%
ENTERPRISE LICENSE2019 Retinal Pharmaceuticals
Market Report
$10,950 (Price includes a printable PDF and supplemental Excel file with all the
tables and figures in the report)
SINGLE‐USER LICENSE2019 Retinal Pharmaceuticals
Market Report
$7,300Printed Copy $250
ONE‐YEAR SUBSCRIPTION Ophthalmic Market
Perspectives Newsletter
$1,000
Order your “2019 Retinal Pharmaceuticals Market Report” now at www.market‐scope.com or contact us directly via email or phone.
Our ProcessMarket Scope’s industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:
Our proprietary global disease population and demographic models Analysis of company‐published financial reports Focused coverage of ophthalmic scientific research, business news, and other activities Attendance and participation in worldwide ophthalmic meetings Interviews and relationships with company executives and practicing physicians
314.835.0600 | info@market-scope.com
How to Order
International Shipping $50
The primary purpose of this report is to analyze the 2019 market in the treatment of retinal diseases and discuss important trends and key factors for future market success. The report looks at the market’s evolution and forecasts growth over the next five years for eight regional markets.
top related